ERBB2 and breast carcinoma: Interestingly, higher expression of the FOXC1 signature conferred a significantly greater probability of relapse-free survival in only the Luminal B (Fig. 6e) and HER2+ breast cancer patients (Supplementary Figure 5H, I).